The focus of recruitment has moved from signing elite talent to stars of the future. It has been funded, often, by the sale ...
Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...